Pharmacokinetics and pathway in the body
In pharmacology, we often encounter a situation where a molecule on its own is unable to produce the desired therapeutic effect. The drug we are examining is a classic example of a prodrug. Chemically, it is a sydnonimine derivative. To start working and exerting its effect on blood vessels, it must pass through a kind of "chemical laboratory" within our body.
The drug is prescribed exclusively orally, meaning it is taken by mouth. After passing through the gastrointestinal tract, its bioavailability reaches 60–70%. This is a very solid pharmacokinetic indicator, meaning that more than half of the administered dose successfully overcomes primary barriers, avoids complete destruction, and enters the systemic circulation.
Regarding elimination, the body gets rid of the resulting metabolites predominantly via the kidneys. The excretion process occurs quite rapidly: the half-life ($t_{1/2}$) ranges from 0.85 to 2.35 hours, which requires an appropriate dosing regimen to maintain a stable prophylactic effect.
Cascade of metabolic transformations
The most interesting part of the pharmacokinetics of this sydnonimine derivative is the unique process of its activation. The mechanism of its antianginal action is entirely tied to the release of nitric oxide (NO), but the path to this molecular event consists of three strict sequential steps:
- Enzymatic step in the liver. After absorption, the initial inactive molecule enters the liver via the bloodstream. There, it undergoes biotransformation and is converted into its first active compound, which in pharmacology is designated as the SIN-1 metabolite.
- Spontaneous non-enzymatic transformation. The further fate of the molecule is extremely noteworthy. The SIN-1 metabolite turns into the next substance — SIN-1A — via an entirely non-enzymatic pathway. This means that no bodily enzymes are needed for this chemical reaction to occur; the process proceeds spontaneously. The resulting SIN-1A metabolite is an extremely unstable compound.
- Generation of nitric oxide. It is this unstable intermediate product (SIN-1A) that acts as the final link and directly releases the NO molecule. Nitric oxide, in turn, triggers intracellular cascades leading to the relaxation of vascular smooth muscle, which completely replicates the classic mechanism of action of nitrates.
Clinical significance and comparison with nitrates
Since the drug requires a certain amount of time for absorption in the gastrointestinal tract and multi-step activation in liver tissues, its pharmacodynamics dictates strict limits for clinical application. The primary and main indication for prescribing it is the prevention of angina attacks.
In clinical practice and pharmacology exams, this sydnonimine derivative is always compared with classic nitrates, as the end result of their work (the release of nitric oxide) is absolutely identical. However, there are two fundamental differences that a medical student must clearly learn:
- Safety profile. The side effects of sydnonimine derivatives are very similar in nature to those of nitrates (which is logical given the shared mechanism of systemic vasodilation), but clinically they are significantly milder, which improves treatment tolerability.
- Absence of pronounced tolerance. This is the most important pharmacological advantage. With prolonged and frequent use of traditional nitrates, their efficacy steadily declines. In the case of the drug in question, tolerance develops to a much lesser extent, allowing it to be used for long-term prophylaxis.
Briefly: answers to topical questions
What is the exact intracellular mechanism of the vasodilating action of nitric oxide released by molsidomine?
Molsidomine is a prodrug: in the liver, it is converted into SIN-1, then SIN-1A is formed, which directly releases nitric oxide (NO). Molsidomine's antianginal mechanism of action is similar to nitrates and is mediated through NO.
To remember the transformation cascade, use the mnemonic chain: Liver — Spontaneity — Oxide. First, the Liver produces SIN-1, then Spontaneously (without enzymes) unstable SIN-1A arises, which immediately yields Oxide (nitric oxide, NO).
Class and exam questions
Why is the drug not used for the emergency relief of an angina attack?
Because it is a prodrug. It requires time for gastrointestinal absorption (bioavailability 60–70%) and multi-step hepatic metabolism to form active metabolites SIN-1 and SIN-1A, which release NO. The main purpose of the drug is prophylaxis.
What is the main advantage over classic nitrates?
The main clinical advantage is that tolerance (habituation) to this agent develops to a significantly lesser extent. In addition, side effects typical of nitrates are milder.
Are enzymes required for the final release of nitric oxide from metabolites?
No. The conversion of the SIN-1 metabolite into unstable SIN-1A occurs non-enzymatically, i.e., without the participation of enzymes. It is SIN-1A that subsequently directly releases nitric oxide.
What else to study on this topic
- Detailed mechanism of vasodilation under the action of nitric oxide (NO).
- Comparative profile of side effects of nitrates and sydnonimine derivatives.
- Causes and mechanisms of tolerance development to antianginal drugs.
- Pharmacokinetics of prodrugs: the impact of liver function on activation rate.
- The role of non-enzymatic reactions in drug metabolism.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Molsidomine" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Cardiovascular Drugs"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.